Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Adjuvant Invasive Urothelial Carcinoma (PROOF 302)
NCT04197986Phase 3Terminated
- Sponsor
- QED Therapeutics
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in urothelial carcinoma (UC) comparing Infigratinib with Placebo (2 arms). Primary endpoint: Disease-free Survival. Started Mar 2020; status: terminated.
02
Drugs
infigratinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04197986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197986.